Antipsychotic Dose Potency: Lurasidone Versus Risperidone
Risperidone is more potent than lurasidone on a milligram basis. [1] Dose-equivalence analyses estimate that risperidone requires a much lower minimum effective daily dose than lurasidone for schizophrenia treatment. [1]
Medication Selection Algorithm
- If milligram potency is the clinical target, risperidone (Risperdal) is selected over lurasidone (Latuda) due to lower minimum effective daily doses in dose-equivalence work. [1]
- If adverse-effect profile and indication are the clinical target, dose potency does not determine agent choice in schizophrenia treatment comparisons. [2]
Key Evidence Supporting This Recommendation
- A minimum effective dose method estimated lurasidone minimum effective daily dose at 40 mg/day versus risperidone at 2 mg/day, implying greater potency for risperidone by approximately 20-fold on a mg/day basis. [1]
- The same dose-equivalence framework concluded that operationalized minimum effective daily doses can be used to estimate clinically equivalent dosing across second-generation antipsychotics. [1]
Monotherapy Versus Combination Therapy
- Potency comparisons between lurasidone and risperidone refer to relative dose requirements and do not change the general principle that antipsychotic regimens can be used as monotherapy or adjunctively based on clinical response and tolerability. [2]
Important Clarifications and Nuances
- “More potent” can be operationalized as “lower dose needed for comparable clinical effect,” which supports a milligram potency advantage for risperidone. [1]
- Binding affinity and receptor occupancy do not translate into a universal clinical potency ranking without a dose-response and exposure model for the specific outcome. [2]
Initiation Thresholds
- Minimum effective daily dose estimates support starting dose selection based on clinically equivalent dosing rather than mg-for-mg assumptions between lurasidone and risperidone. [1]
Common Pitfalls to Avoid
- Using direct mg-to-mg conversions between lurasidone and risperidone overestimates lurasidone exposure relative to risperidone. [1]
Targets or Goals of Therapy
- The therapeutic goal is schizophrenia symptom reduction with tolerability, where agent dosing should be aligned with established dose-equivalence approaches rather than presumed equal mg potency. [1]